Abstract:Background: Pharmacoepidemiology is a discipline that applies epidemiological methodologies to the study of drug use, especially the safety of drug use in a large group of people. But this methodology has not been widely utilized to assess drug safety in pediatrics for children aged between 0 and 18 years. Objectives: (1) To describe current gaps in evaluating pediatric drug safety; (2) to use published examples demonstrating the value of pharmacoepidemiology in detecting and quantifying adverse drug events in pediatrics; (3) to review pharmacoepidemiological study their strengths and limitations, and examples of their applications in the field of drug safety evaluation; and (4) to provide recommendations about selecting an appropriate study design and minimizing a major methodological limitation. Overview: Only about 20% of approved drugs are licensed for pediatric use, and many prescription drugs are used as 'off label' or 'unlicensed' pediatric treatments. Among this small percentage of licensed pediatric drugs, pre-marketing trials may not adequately address all drug-related safety issues in pediatrics. Consequently, an important gap exists in pediatric drug safety evaluation. Pharmacoepidemiology offers a number of advantages in detecting and quantifying adverse drug events in pediatrics. Each pharmacoepidemiological study design has its own strengths and limitations in the evaluation of drug safety. An appropriate study design depends on the underlying research question being addressed. Confounding by indication, the most serious and challenge form of confounding in pharmacoepidemiological designs, could lead to misleading claims about the relationship between drug use and the development of potential adverse drug events, and should be adequately controlled. Conclusions: Pharmacoepiderniology is a powerful methodology that offers many advantages to assess pediatric drug safety such as large sample size, long period of follow-up, and good generalizibility. But this methodology should be applied judiciously to maximize its potential.

Principles and Applications of Pharmacometrics in Drug Evaluation in Children.

Dosage individualization in children: integration of pharmacometrics in clinical practice

Applied pharmacokinetics to improve pharmacotherapy in neonatal and paediatric intensive care units: focus on correct dose selection

Etudes Pharmacocinétiques En Pédiatrie : Pré-Requis, Modélisation Et Analyse De La Variabilité Génétique Et Non-Génétique

Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates.

General Clinical and Methodological Considerations on the Extrapolation of Pharmacokinetics and Optimization of Study Protocols for Small Molecules and Monoclonal Antibodies in Children

Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies

External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: the Transferability of Published Models to Different Clinical Settings.

Pharmacokinetic and pharmacodynamic principles: unique considerations for optimal design of neonatal clinical trials

Role of pharmacoepidemiology in evaluating prescription drug safety in pediatrics.

Population Pharmacokinetic Meta-Analysis of Individual Data to Design the First Randomized Efficacy Trial of Vancomycin in Neonates and Young Infants

Optimization of Vancomycin Initial Dosing Regimen in Neonates Using an Externally Evaluated Population Pharmacokinetic Model

Potentially Harmful Excipients: State of the Art for Oral Liquid Forms Used in Neonatology and Pediatrics Units

Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children

Pharmacogenetic Aspects of Drug Metabolizing Enzymes and Transporters in Pediatric Medicine: Study Progress, Clinical Practice and Future Perspectives

Pharmacometric in silico studies used to facilitate a national dose standardisation process in neonatology – application to amikacin

Physiologically Based Pharmacokinetic Modeling of Vancomycin and its Comparison with Population Pharmacokinetic Model in Neonates

Current Knowledge, Challenges and Innovations in Developmental Pharmacology: A Combined Conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper

O26 Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young Infants

Vancomycin Population Pharmacokinetic Modeling in Children Using Bayesian Estimation and a Non Parametric Approach

Predictive Performance of Pharmacokinetic Model-Based Virtual Trials of Vancomycin in Neonates: Mathematics Matches Clinical Observation